FindTrial
Sign In

Singl+86

Single-arm, multicentre, open-label clinical study evaluating the efficacy and safety of adalimumab for nail psoriasis with non-invasive method

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065560
Enrollment
Unknown
Registered
2022-11-08
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nail psoriasis

Interventions

A-group:Adalimumab Solution for Injection

Sponsors

The Eighth Affiliated Hospital Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Both men and women over 18 years old 2. Understanding the procedure and content of the trial and signing the informed consent voluntarily . 3. Previous or present diagnosis of psoriasis vulgaris. 4. Moderate-severe psoriasis was diagnosed (more than 4 nails involved OR NAPSI>20).

Exclusion criteria

Exclusion criteria: 1. Using TNFa inhibitors previously. 2. Complicated with serious heart and brain, liver and kidney, hematopoietic system disease and malignant tumor. 3. Complicated with demyelinating diseases and connective tissue diseases. 4. Active tuberculosis, hepatitis and other active period of infection. 5. Participating in other clinical trials at the same time or finishing less than 30 days. 6. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
NAPSI score(W12?24);—

Secondary

MeasureTime frame
Proportion of patients with NAPSI 50 (W4, 12, 24);NAPPA QoL score(W4?12?24);—

Countries

China

Contacts

Public ContactZhang zhenying

The Eighth Affiliated Hospital Sun Yat-sen University

zhangzhy276@mail.sysu.edu.cn+86 13923848084

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026